Download - SWOT Analysis of NOVARTIS
A GLOBAL HEALTHCARE COMPANY
byPIYUSH [email protected]
Swiss MN Pharmaceutical CompanyCreated in 1996 through a merger of Ciba-Geigy & SandozHeadquartered in Basel, SwitzerlandEmploys nearly 1,19,000 people in 140 countriesSubsidiaries:-
NOVARTIS INTERNATIONAL AG
Better Patient Outcomes by focusing our Resources on developing medicines Science Based Innovation by maintaining substantial investment in R&DLead in Growing Areas of Healthcare by focusing on patented medicines, generics and eye care.
STRATEGYto be the world’s most respected and successful healthcare company …..
Currency inMillions of US Dollars
Dec 312011
Dec 312012
Dec 312013
Dec 312014
TOTAL REVENUES
59,375.0 51,971.0 52,716.0 53,634.0
GROSS PROFIT
40,804.0 36,385.0 36,177.0 36,431.0
OPERATING EXPENSES
28,040.0 24,000.0 24,706.0 24,511.0
OPERATING INCOME
12,764.0 12,385.0 11,471.0 11,920.0
NET INTEREST EXPENSE
-688.0 -673.0 -648.0 -670.0
NET INCOME 9,113.0 9,270.0 9,175.0 10,210.0
FINANCIAL STATEMENT*
*http://www.bloomberg.com/research/stocks/financials/financials.asp
NET INCOME : YEARLY
Jan/11Jan/12
Jan/13Jan/14
84008600880090009200940096009800
100001020010400
9113.00* 9270.00*9175.00*
10210.00*
*CURRENCY IN MILLIONS OF US DOLLARS
Novartis has raised the bar in driving an execution strategy for industrial data, taking advantage of an integrated data infrastructure to improve quality, consistency and productivity across sites while reducing industrial automation and IT costs.Novartis is bringing together Information Technology (IT) and Operational Technology (OT) within their organization and creating a powerful manufacturing engine with Operational Intelligence.
OPERATIONAL DATA
SWOT ANALYSIS :1/4STRENGTHS
Expanded Business Model including Pharmaceutical Unit, Eye Care & Generics, Vaccines etc.Biotechnology Firm “Chiron” was acquired by Novartis AG, a Unique & Profitable step.A Huge Range of Investments.>200 Projects in Clinical Development including 141 in Pharmaceutical Division, as of July 21, 2015.Had a Market-cap of around $280 Billion, largest healthcare company by this metric.
Loss of Patents
Patent protection for a major cancer drug “Glivec”, rejected in India.
FDA delays approval of an oral ant-diabetic drug “Galvus”.
Has not Separate Unit for Pediatrics
WEAKNESSES SWOT
ANALYSIS :2/4
Has a potential to enhance “Sandoz” unit as leading “state-of-the-art” biosimilars manufacturer.
Can contribute its products & services for pediatrics.
Novartis said that it won’t invest on R&D in India, but they should have contribute R&D here because India is a very favorable country for trials.
OPPORTUNITIESSWOT
ANALYSIS :3/4
FDA Warnings : Manufacturing unit in Unterach am Attersee, Austria.
Criminal investigation of its marketing practices in Japan for a popular blood pressure medicine “Diovan”.
Patent expiration & longer term risk of patent expiry for “Glivec”.
THREATS SWOT ANALYSIS :4/4
https://www.novartis.comhttp://www.bloomberg.comhttp://www.pharmafile.com/news/179555/novartis-receives-fda-warning
REFERENCES